ArticleInternational journal of breast cancer2021

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Tamera J Lillemoe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.